Aduro discontinues development of CRS-207

Aduro Biotech Inc. (NASDAQ:ADRO) said it will discontinue development of CRS-207 based on "insufficient clinical activity" in Phase I/II trials of the candidate to treat mesothelioma and

Read the full 274 word article

User Sign In